company background image
KRKG

Krka d. dLJSE:KRKG Stock Report

Market Cap

€3.6b

7D

-2.9%

1Y

31.8%

Updated

01 Dec, 2021

Data

Company Financials +
KRKG fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends5/6

KRKG Stock Overview

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.

Krka d. d Competitors

Viatris

NasdaqGS:VTRS

US$14.9b

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.1b

Bausch Health Companies

NYSE:BHC

US$8.6b

Hikma Pharmaceuticals

LSE:HIK

UK£5.1b

Price History & Performance

Summary of all time highs, changes and price drops for Krka d. d
Historical stock prices
Current Share Price€116.50
52 Week High€121.00
52 Week Low€88.20
Beta0.44
1 Month Change4.96%
3 Month Change4.48%
1 Year Change31.79%
3 Year Change110.29%
5 Year Change115.74%
Change since IPO1,368.83%

Recent News & Updates

Nov 24
Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?

Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?

Does the November share price for Krka, d. d. ( LJSE:KRKG ) reflect what it's really worth? Today, we will estimate the...

Oct 30
Here's Why We Think Krka d. d (LJSE:KRKG) Is Well Worth Watching

Here's Why We Think Krka d. d (LJSE:KRKG) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Aug 11
Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?

Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?

Does the August share price for Krka, d. d. ( LJSE:KRKG ) reflect what it's really worth? Today, we will estimate the...

Shareholder Returns

KRKGSI PharmaceuticalsSI Market
7D-2.9%-0.8%-2.2%
1Y31.8%17.4%38.4%

Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned 16.8% over the past year.

Return vs Market: KRKG underperformed the SI Market which returned 38.8% over the past year.

Price Volatility

Is KRKG's price volatile compared to industry and market?
KRKG volatility
KRKG Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement2.7%
10% most volatile stocks in SI Market6.0%
10% least volatile stocks in SI Market2.4%

Stable Share Price: KRKG is not significantly more volatile than the rest of SI stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: KRKG's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
195411,470Jože Colarichttps://www.krka.biz

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular diseases; the gastrointestinal tract; central nervous system; pain relief; anti-infectives; blood and blood-forming organs; urological; diabetes; and oncology. The company also provides non-prescription products, such as products for oral cavity and pharynx; cough and cold products; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.

Krka d. d Fundamentals Summary

How do Krka d. d's earnings and revenue compare to its market cap?
KRKG fundamental statistics
Market Cap€3.63b
Earnings (TTM)€320.24m
Revenue (TTM)€1.55b

11.3x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KRKG income statement (TTM)
Revenue€1.55b
Cost of Revenue€676.85m
Gross Profit€874.47m
Expenses€554.23m
Earnings€320.24m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Jan 27, 2022

Earnings per share (EPS)10.28
Gross Margin56.37%
Net Profit Margin20.64%
Debt/Equity Ratio0%

How did KRKG perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

49%

Payout Ratio

Valuation

Is Krka d. d undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KRKG (€116.5) is trading below our estimate of fair value (€235.85)

Significantly Below Fair Value: KRKG is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KRKG is good value based on its PE Ratio (11.3x) compared to the European Pharmaceuticals industry average (27.1x).

PE vs Market: KRKG is poor value based on its PE Ratio (11.3x) compared to the SI market (10x).


Price to Earnings Growth Ratio

PEG Ratio: KRKG's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: KRKG is good value based on its PB Ratio (2x) compared to the XE Pharmaceuticals industry average (3.1x).


Future Growth

How is Krka d. d forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-0.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KRKG's earnings are forecast to decline over the next 3 years (-0.6% per year).

Earnings vs Market: KRKG's earnings are forecast to decline over the next 3 years (-0.6% per year).

High Growth Earnings: KRKG's earnings are forecast to decline over the next 3 years.

Revenue vs Market: KRKG's revenue (2.1% per year) is forecast to grow slower than the SI market (2.9% per year).

High Growth Revenue: KRKG's revenue (2.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KRKG's Return on Equity is forecast to be low in 3 years time (12.4%).


Past Performance

How has Krka d. d performed over the past 5 years?

22.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KRKG has high quality earnings.

Growing Profit Margin: KRKG's current net profit margins (20.6%) are higher than last year (18.2%).


Past Earnings Growth Analysis

Earnings Trend: KRKG's earnings have grown significantly by 22.2% per year over the past 5 years.

Accelerating Growth: KRKG's earnings growth over the past year (12.6%) is below its 5-year average (22.2% per year).

Earnings vs Industry: KRKG earnings growth over the past year (12.6%) underperformed the Pharmaceuticals industry 12.6%.


Return on Equity

High ROE: KRKG's Return on Equity (17.2%) is considered low.


Financial Health

How is Krka d. d's financial position?


Financial Position Analysis

Short Term Liabilities: KRKG's short term assets (€1.4B) exceed its short term liabilities (€320.1M).

Long Term Liabilities: KRKG's short term assets (€1.4B) exceed its long term liabilities (€173.0M).


Debt to Equity History and Analysis

Debt Level: KRKG is debt free.

Reducing Debt: KRKG had no debt 5 years ago.

Debt Coverage: KRKG has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: KRKG has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Krka d. d current dividend yield, its reliability and sustainability?

4.29%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: KRKG's dividend (4.29%) is higher than the bottom 25% of dividend payers in the SI market (3.67%).

High Dividend: KRKG's dividend (4.29%) is low compared to the top 25% of dividend payers in the SI market (4.88%).


Stability and Growth of Payments

Stable Dividend: KRKG's dividends per share have been stable in the past 10 years.

Growing Dividend: KRKG's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (48.7%), KRKG's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: KRKG's dividends in 3 years are forecast to be covered by earnings (62.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.8yrs

Average management tenure


CEO

Jože Colaric (66 yo)

16.83yrs

Tenure

€1,232,000

Compensation

Dr. Jože Colaric has been the Chief Executive Officer and President of the Management Board at KrKa dd Novo Mesto since January 1, 2005. Dr. Colaric has been Member of the Management Board at KrKa dd Novo...


CEO Compensation Analysis

Compensation vs Market: Jože's total compensation ($USD1.40M) is about average for companies of similar size in the SI market ($USD1.53M).

Compensation vs Earnings: Jože's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: KRKG's management team is seasoned and experienced (10.8 years average tenure).


Board Members

Experienced Board: KRKG's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Krka, d. d.'s employee growth, exchange listings and data sources


Key Information

  • Name: Krka, d. d.
  • Ticker: KRKG
  • Exchange: LJSE
  • Founded: 1954
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.629b
  • Shares outstanding: 31.15m
  • Website: https://www.krka.biz

Number of Employees


Location

  • Krka, d. d.
  • Šmarješka cesta 6
  • Novo Mesto
  • 8501
  • Slovenia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 22:00
End of Day Share Price2021/12/01 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.